PRINCETON, N.J. --(BUSINESS WIRE)--Mar. 1, 2023-- UroGen Pharma Ltd. (Nasdaq: URGN), a biotech company dedicated to developing and commercializing innovative solutions that treat urothelial and specialty cancers, today announced that it will present at the following investor conferences in March:
--In a Small Feasibility Study, UGN-102 Achieves a Complete Response in 75% (6 of 8) Patients --UGN-102 is Being Studied in Low-Grade Intermediate-Risk Non-Muscle Invasive Bladder Cancer PRINCETON, N.J. --(BUSINESS WIRE)--Feb. 15, 2023-- UroGen Pharma Ltd.
PRINCETON, N.J. --(BUSINESS WIRE)--Jan. 11, 2023-- UroGen Pharma Ltd. (Nasdaq: URGN), a biotech company dedicated to developing and commercializing innovative solutions that treat urothelial and specialty cancers, today highlights results from the first and largest post-commercial utilization
--If approved, UGN-102 would be the first non-surgical primary therapeutic to treat a subset of bladder cancer characterized by high recurrence rates and multiple surgeries PRINCETON, N.J. --(BUSINESS WIRE)--Dec. 19, 2022-- UroGen Pharma Ltd. (Nasdaq: URGN), a biotech company dedicated to
PRINCETON, N.J. --(BUSINESS WIRE)--Dec. 9, 2022-- UroGen Pharma Ltd. (Nasdaq: URGN) a biotech company dedicated to developing and commercializing innovative solutions that treat urothelial and specialty cancers, today announced the grants of inducement restricted stock units (“RSUs”) to 12 new
-- Results from this ongoing, noninterventional rollover study were presented at the 23 rd Annual Society of Urological Oncology (SUO) Meeting in San Diego SAN DIEGO --(BUSINESS WIRE)--Dec. 2, 2022-- UroGen Pharma Ltd. (Nasdaq: URGN), a biotech company dedicated to developing and commercializing
--Results from this ongoing, non-interventional, rollover study were presented at the 23 rd Annual Society of Urologic Oncology (SUO) Meeting in San Diego SAN DIEGO --(BUSINESS WIRE)--Dec. 1, 2022-- UroGen Pharma Ltd. (Nasdaq: URGN), a biotech company dedicated to creating novel solutions that
- Fireside Chat November 29, 2022 from 3:55 – 4:15 PM ET - PRINCETON, N.J. --(BUSINESS WIRE)--Nov. 21, 2022-- UroGen Pharma Ltd. (Nasdaq: URGN), a biotech company dedicated to developing and commercializing innovative solutions that treat urothelial and specialty cancers, today announced that it
-- 32-patient, multi-center study showed 9% occurrence of ureteral stenosis and 10% discontinuation rate -- All three stenosis patients were treated without later recurrence or chronic stenosis PRINCETON, N.J. --(BUSINESS WIRE)--Nov. 14, 2022-- UroGen Pharma Ltd.
Full enrollment of ENVISION Phase 3 pivotal trial with UGN-102 in low-grade intermediate-risk non-muscle invasive bladder cancer (LG-IR-NMIBC) expected as soon as the end of November 2022 ; NDA submission anticipated in first half of 2024 Reported JELMYTO® net product revenue of $16.1 million , an
